Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI Hong Kong ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI Hong Kong ETF trades at $21.72 (market cap $1.15B). The key difference: iShares MSCI Hong Kong ETF is far larger — about 171.9× Enveric Biosciences Inc's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI Hong Kong ETF for 61 Days on average.
| ENVB | EWH | |
|---|---|---|
Market Cap | $6.69M | $1.15B |
Volume | 41,141 | 2,444,357 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $24.55 |
52-Week Low | $1.27 | $20.66 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
EWH trades at $21.58, down 0.19% with a bearish technical signal as moving averages show strong selling pressure. The ETF tracks Hong Kong's Hang Seng Index, which has faced significant volatility due to US-China tensions and Federal Reserve policy concerns. Recent institutional selling by Empowered Funds LLC (70.2% reduction in Q2 2026) reflects cautious sentiment toward Hong Kong markets.
Outlook remains challenged by geopolitical risks and Hong Kong market volatility, though oversold RSI levels suggest potential for near-term technical bounce. Key risks include continued US-China tensions and Fed policy uncertainty, while opportunities exist if Hong Kong equities stabilize. The ETF lacks fundamental metrics as it tracks an index rather than operating as a standalone company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
